Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC
Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have shown encouraging clinical benefits for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC). Nevertheless, therapeutic efficacy and wide clinical applicability remain a challenge due to “cold” tumors’ immunological characteristics. Tumor immunosuppressive microenvironment (TIME) continuously natural force for immune escape by extracellular matrix (ECM) infiltration, tumor angiogenesis, and tumor cell proliferation. Herein, we proposed a novel concept by multi-overcoming immune escape to maximize the ICIs combined with antiangiogenic therapy efficacy against HCC. A self-delivery photothermal-boosted-NanoBike (BPSP) composed of black phosphorus (BP) tandem-augmented anti-PD-L1 mAb plus sorafenib (SF) is meticulously constructed as a triple combination therapy strategy. The simplicity of BPSP's composition, with no additional ingredients added, makes it easy to prepare and presents promising marketing opportunities. (1) NIR-II-activated BPSP performs photothermal therapy (PTT) and remodels ECM by depleting collagen I, promoting deep penetration of therapeutics and immune cells. (2) PTT promotes SF release and SF exerts anti-vascular effects and down-regulates PD-L1 via RAS/RAF/ERK pathway inhibition, enhancing the efficacy of anti-PD-L1 mAb in overcoming immune evasion. (3) Anti-PD-L1 mAb block PD1/PD-L1 recognition and PTT-induced ICD initiates effector T cells and increases response rates of PD-L1 mAb. Highly-encapsulated BPSP converted 'cold' tumors into 'hot' ones, improved CTL/Treg ratio, and cured orthotopic HCC tumors in mice. Thus, multi-overcoming immune escape offers new possibilities for advancing immunotherapies, and photothermal/chemical/immune synergistic therapy shows promise in the clinical development of HCC. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of nanobiotechnology - 22(2024), 1 vom: 29. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Huizhen [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Anti-vascular therapy |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12951-024-02399-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055350569 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055350569 | ||
| 003 | DE-627 | ||
| 005 | 20240330064640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240330s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12951-024-02399-3 |2 doi | |
| 035 | |a (DE-627)SPR055350569 | ||
| 035 | |a (SPR)s12951-024-02399-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 084 | |a 58.30 |2 bkl | ||
| 084 | |a 50.94 |2 bkl | ||
| 100 | 1 | |a Yang, Huizhen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have shown encouraging clinical benefits for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC). Nevertheless, therapeutic efficacy and wide clinical applicability remain a challenge due to “cold” tumors’ immunological characteristics. Tumor immunosuppressive microenvironment (TIME) continuously natural force for immune escape by extracellular matrix (ECM) infiltration, tumor angiogenesis, and tumor cell proliferation. Herein, we proposed a novel concept by multi-overcoming immune escape to maximize the ICIs combined with antiangiogenic therapy efficacy against HCC. A self-delivery photothermal-boosted-NanoBike (BPSP) composed of black phosphorus (BP) tandem-augmented anti-PD-L1 mAb plus sorafenib (SF) is meticulously constructed as a triple combination therapy strategy. The simplicity of BPSP's composition, with no additional ingredients added, makes it easy to prepare and presents promising marketing opportunities. (1) NIR-II-activated BPSP performs photothermal therapy (PTT) and remodels ECM by depleting collagen I, promoting deep penetration of therapeutics and immune cells. (2) PTT promotes SF release and SF exerts anti-vascular effects and down-regulates PD-L1 via RAS/RAF/ERK pathway inhibition, enhancing the efficacy of anti-PD-L1 mAb in overcoming immune evasion. (3) Anti-PD-L1 mAb block PD1/PD-L1 recognition and PTT-induced ICD initiates effector T cells and increases response rates of PD-L1 mAb. Highly-encapsulated BPSP converted 'cold' tumors into 'hot' ones, improved CTL/Treg ratio, and cured orthotopic HCC tumors in mice. Thus, multi-overcoming immune escape offers new possibilities for advancing immunotherapies, and photothermal/chemical/immune synergistic therapy shows promise in the clinical development of HCC. Graphical Abstract | ||
| 650 | 4 | |a Immune checkpoint inhibitors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Black phosphorus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tumor immunosuppressive |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immune escape |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anti-vascular therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hepatocellular carcinoma |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mu, Weiwei |4 aut | |
| 700 | 1 | |a Yuan, Shijun |4 aut | |
| 700 | 1 | |a Yang, Han |4 aut | |
| 700 | 1 | |a Chang, Lili |4 aut | |
| 700 | 1 | |a Sang, Xiao |4 aut | |
| 700 | 1 | |a Gao, Tong |4 aut | |
| 700 | 1 | |a Liang, Shuang |4 aut | |
| 700 | 1 | |a Liu, Xiaoqing |4 aut | |
| 700 | 1 | |a Fu, Shunli |4 aut | |
| 700 | 1 | |a Zhang, Zipeng |4 aut | |
| 700 | 1 | |a Liu, Yongjun |4 aut | |
| 700 | 1 | |a Zhang, Na |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nanobiotechnology |d BioMed Central, 2003 |g 22(2024), 1 vom: 29. März |w (DE-627)SPR02945347X |w (DE-600)2100022-0 |x 1477-3155 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:29 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12951-024-02399-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 58.30 |q VZ |
| 936 | b | k | |a 50.94 |q VZ |
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |b 29 |c 03 | ||